Related Experiment Video

Updated: May 8, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Tofacitinib prevents radiographic progression in rheumatoid arthritis

Joon Wan Kim1, In Ah Choi, Eun Young Lee

  • 1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

Journal of Korean Medical Science
|August 21, 2013
PubMed

Insights

Tofacitinib, a Janus kinase inhibitor, significantly reduced joint damage in rheumatoid arthritis (RA) patients compared to conventional DMARDs. This study shows tofacitinib

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and progressive structural damage.
  • Conventional disease-modifying antirheumatic drugs (DMARDs) are standard treatments, but their efficacy in preventing long-term structural damage can vary.
  • Janus kinase (JAK) inhibitors represent a newer class of targeted therapies for RA.

Purpose of the Study:

  • To evaluate the efficacy of tofacitinib in preventing radiographic progression of hand joints in rheumatoid arthritis (RA) patients.
  • To compare the structural damage progression in RA patients treated with tofacitinib versus conventional DMARDs over 18 months.

Main Methods:

  • A cohort study comparing 21 RA patients treated with tofacitinib to 42 RA patients treated with conventional DMARDs.
  • Radiographic progression of hand joints was assessed using the simple erosion narrowing score over an 18-month period.
  • Within the tofacitinib group, changes in radiographic scores before and after treatment were analyzed.

Main Results:

  • Tofacitinib treatment resulted in significantly less erosion and sum score progression compared to conventional DMARDs (P = 0.038 for erosion, P = 0.012 for sum).
  • Joint space narrowing (JSN) progression was also less in the tofacitinib group (P = 0.055).
  • In the tofacitinib group, yearly rates of erosion, JSN, and sum score significantly decreased after treatment initiation (P < 0.001 for sum score).

Conclusions:

  • Tofacitinib demonstrates potential in preventing structural joint damage in rheumatoid arthritis.
  • The findings suggest that tofacitinib may be a valuable therapeutic option for RA patients at risk of progressive joint destruction.
Keywords:
Arthritis, RheumatoidRadiographic ProgressionTofacitinib

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...